Refining Vancomycin Protein Binding Estimates: Identification of Clinical Factors That Influence Protein Binding

ABSTRACT While current data indicate only free (unbound) drug is pharmacologically active and is most predictive of response, pharmacodynamic studies of vancomycin have been limited to measurement of total concentrations. The protein binding of vancomycin is thought to be approximately 50%, but considerable variability surrounds this estimate. The present study sought to determine the extent of vancomycin protein binding, to identify factors that modulate its binding, and to create and validate a prediction tool to estimate the extent of protein binding based on individual clinical factors. This single-site prospective cohort study included hospitalized adult patients treated with vancomycin and with a vancomycin serum concentration determination available. Linear regression was used to predict the free vancomycin concentration (f[vanco]) and to determine the clinical factors modulating vancomycin protein binding. Among the 50 patients in the study, the mean protein binding was 41.5%. The strongest predictor of f[vanco] was the total vancomycin concentration (total [vanco]), and this was modified by dialysis and total protein of ≥6.7 g/dl as covariates. The algebraic expression from the final prediction model was f[vanco] = 0.643 + 0.560 × total [vanco] − {0.067 × total [vanco] × D} − {0.071 × total [vanco] × TP} where D = 1 if dialysis dependent or 0 if not dialysis dependent, and TP = 1 if total protein is ≥6.7 g/dl or 0 if total protein is <6.7 g/dl. The R2 of the final prediction model was 0.959 (P < 0.001). Validation of our model was performed in 13 patients, and the predictive performance was highly favorable (R2 was 0.9, and bias and precision were 0.18 and 0.18, respectively). Prediction models such as ours can be utilized in future pharmacokinetics and pharmacodynamics studies evaluating the exposure-response profile and to determine the pharmacodynamic target of interest as it relates to the free concentration.

[1]  W. Craig,et al.  Significance of serum protein and tissue binding of antimicrobial agents. , 1976, Annual review of medicine.

[2]  M. Rybak,et al.  Vancomycin pharmacokinetics in burn patients and intravenous drug abusers , 1990, Antimicrobial Agents and Chemotherapy.

[3]  D. Nathwani,et al.  Protein binding and serum bactericidal activities of vancomycin and teicoplanin , 1995, Antimicrobial agents and chemotherapy.

[4]  W. Craig Basic pharmacodynamics of antibacterials with clinical applications to the use of beta-lactams, glycopeptides, and linezolid. , 2003, Infectious disease clinics of North America.

[5]  W. Craig,et al.  Pharmacokinetic/pharmacodynamic Parameters: Rationale for Antibacterial Dosing of Mice and Men Tions Were Associated with Only a Slight Reduction in Bacterial , 2022 .

[6]  G. Rolinson,et al.  Effect of protein binding on antibiotic activity in vivo. , 1983, The Journal of antimicrobial chemotherapy.

[7]  D. Levine,et al.  Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. , 2009, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[8]  J. Rotschafer,et al.  The influence of serum albumin and alpha 1-acid glycoprotein on vancomycin protein binding in patients with burn injuries. , 1989, The Journal of burn care & rehabilitation.

[9]  M. H. Gault,et al.  Prediction of creatinine clearance from serum creatinine. , 1975, Nephron.

[10]  J. Leonard,et al.  Human serum alpha 1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease , 1996, Antimicrobial agents and chemotherapy.

[11]  G. Rolinson,et al.  The binding of antibiotics to serum proteins. , 1965, British journal of pharmacology and chemotherapy.

[12]  W. Mcdermott,et al.  The Relation of Protein Binding to the Pharmacology and Antibacterial Activity of Penicillins X, G, Dihydro F, and K. , 1947, Journal of bacteriology.

[13]  M. Rybak,et al.  Prediction Model to Identify Patients With Staphylococcus aureus Bacteremia at Risk for Methicillin Resistance , 2003, Infection Control &#x0026; Hospital Epidemiology.

[14]  George L. Drusano,et al.  Antimicrobial pharmacodynamics: critical interactions of 'bug and drug' , 2004, Nature Reviews Microbiology.

[15]  M. Rybak,et al.  The pharmacokinetic and pharmacodynamic properties of vancomycin. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  A. Dreisbach,et al.  The effect of chronic renal failure on drug metabolism and transport , 2008, Expert opinion on drug metabolism & toxicology.

[17]  J. Rotschafer,et al.  Vancomycin pharmacokinetics in patients with various degrees of renal function , 1988, Antimicrobial Agents and Chemotherapy.

[18]  D. Krogstad,et al.  Single‐Dose Kinetics of Intravenous Vancomycin , 1980, Journal of clinical pharmacology.

[19]  B. Guglielmo,et al.  Effect of protein binding on serum bactericidal activities of ceftazidime and cefoperazone in healthy volunteers , 1988, Antimicrobial Agents and Chemotherapy.

[20]  E. Maderazo,et al.  Serum protein-binding characteristics of vancomycin , 1993, Antimicrobial Agents and Chemotherapy.

[21]  M. Rybak Pharmacodynamics: relation to antimicrobial resistance. , 2006, The American journal of medicine.

[22]  P. Tulkens,et al.  International Journal of Antimicrobial Agents Correlation between Free and Total Vancomycin Serum Concentrations in Patients Treated for Gram-positive Infections , 2022 .

[23]  Burton H. Singer,et al.  Recursive partitioning in the health sciences , 1999 .

[24]  G. Kaatz,et al.  Comparative effect of protein binding on the killing activities of teicoplanin and vancomycin , 1991, Antimicrobial Agents and Chemotherapy.

[25]  B. Ackerman,et al.  Vancomycin Serum Protein Binding Determination by Ultrafiltration , 1988, Drug intelligence & clinical pharmacy.

[26]  E. Lee,et al.  Pharmacokinetics of Intravenous Vancomycin in Patients with End‐Stage Renal Failure , 1990, Therapeutic drug monitoring.

[27]  D. Elliott,et al.  Protein binding of vancomycin in a patient with immunoglobulin A myeloma , 1990, Antimicrobial Agents and Chemotherapy.

[28]  Jerome J. Schentag,et al.  Pharmacodynamics of Vancomycin and Other Antimicrobials in Patients with Staphylococcus aureus Lower Respiratory Tract Infections , 2004, Clinical pharmacokinetics.

[29]  Jessina C. McGregor,et al.  Controlling for Severity of Illness in Outcome Studies Involving Infectious Diseases: Impact of Measurement at Different Time Points , 2008, Infection Control &#x0026; Hospital Epidemiology.

[30]  L. Lesko,et al.  Vancomycin disposition: The importance of age , 1984, Clinical pharmacology and therapeutics.

[31]  L. Albrecht,et al.  Vancomycin Protein Binding in Patients with Infections Caused by Staphylococcus Aureus , 1991, DICP : the annals of pharmacotherapy.

[32]  H. L. Ragsdale,et al.  Ultrafiltration is theoretically equivalent to equilibrium dialysis but much simpler to carry out. , 1978, Archives of biochemistry and biophysics.

[33]  E. Draper,et al.  APACHE II: A severity of disease classification system , 1985, Critical care medicine.